Idorsia Ltd
🇨🇭Switzerland
A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Midazolam and Warfarin in Healthy Male Subjects
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT05480488
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany
A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Dabigatran and Rosuvastatin in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05480475
- Locations
- 🇨🇿
CEPHA s.r.o., Pilsen, Czechia
A Study to Investigate the Effects of Daridorexant on Nighttime Breathing in Patients With Shallow or Paused Breath During Sleep
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05458193
- Locations
- 🇩🇪
ASR Advanced Sleep Research GmbH, Berlin, Germany
Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT05423717
- Locations
- 🇺🇸
University of South Florida - Tampa General Hospital (TGH), Tampa, Florida, United States
🇺🇸Encore Medical Research of Weston, Weston, Florida, United States
🇺🇸Banner - University Medical Center Tucson, Tucson, Arizona, United States
A Study to Investigate the Effect of Single and Repeated Oral Doses of ACT-539313 on What the Body Does to Flurbiprofen, Omeprazole, Midazolam in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT05254548
- Locations
- 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
Bioequivalence Study of Different Aprocitentan Tablet Formulations
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT05196399
- Locations
- 🇨🇿
CEPHA s.r.o., Pilsen, Czechia
Pharmacokinetics of Omeprazole and Midazolam When Co-administered With ACT-1014-6470
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05123820
- Locations
- 🇨🇿
CEPHA s.r.o., Pilsen, Czechia
The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT05004311
- Locations
- 🇵🇹
BlueClinical Phase 1 Hospital de Prelado, Porto, Portugal
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 14000
- Registration Number
- NCT04957719
- Locations
- 🇭🇺
Uzsoki Utcai Kórház, Budapest, Hungary
🇭🇺Debreceni Egyetem Klinikai Központ Kardiológiai és Szívsebészeti Klinika, Debrecen, Hungary
🇺🇸Amarillo Heart Clinical Research Institute Inc., Amarillo, Texas, United States
A Study to Investigate the Pharmacokinetics of ACT-1014-6470 in Subjects With Severe Renal Impairment Compared to Control Subjects
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2021-11-29
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04899219
- Locations
- 🇩🇪
APEX GmbH, Munich, Germany
© Copyright 2024. All Rights Reserved by MedPath